The EPS projection of PTC Therapeutics, Inc. (NASDAQ:PTCT) for quarter ended 2016-09-30 is $-1.12. Last week, the EPS forecast was $-1.12 against target of $-1.12, a month earlier. Two months ago, this estimate was $-1.12 versus forecast of $-1.12 three months earlier, implying a deviation of 0%.
PTC Therapeutics, Inc. (NASDAQ:PTCT) stated that 18 days ago, its stock price was positively revised 1 times while negative revisions were 1.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 0, 2, and 2, correspondingly.
EPS estimate downgrade for PTC Therapeutics, Inc. (NASDAQ:PTCT) in the preceding 30, 120, 60 and 90 days were 0, 1, 1, and 1, correspondingly.
PTC Therapeutics, Inc. (NASDAQ:PTCT) EPS target for the quarter closed 1 was $-1.12, based on 6 recommendations. As reported on 2016-05-05 the EPS was $-1.16. The change was $0.05, implying a percentage deviation of 4.13%. The projections showed a standard deviation of 0.24.
Quarterly Sales Estimates
PTC Therapeutics, Inc. (NASDAQ:PTCT) yearly sales prediction for the fiscal 2016 stands at $22.63 and the median estimate is at $21.901. Almost 3 analysts issued sales target.
Highest sales target is $25.89 while the lowest target is $20.1 showing standard deviation of 2.963%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that the deviation in forecast was -3.537%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...